TuisABUS • NASDAQ
add
Arbutus Biopharma Corp
Vorige sluiting
$4,79
Dagwisseling
$4,66 - $4,82
Jaarwisseling
$2,71 - $5,10
Markkapitalisasie
919,31 m USD
Gemiddelde volume
1,25 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 529,00 k | -60,49% |
Bedryfskoste | 3,04 m | -32,91% |
Netto inkomste | -7,74 m | 60,73% |
Netto winsgrens | -1,46 k | 0,61% |
Wins per aandeel | -0,06 | 59,57% |
EBITDA | -8,28 m | 51,67% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 93,70 m | -26,68% |
Totale bates | 97,71 m | -30,43% |
Totale aanspreeklikheid | 20,31 m | -39,46% |
Totale ekwiteit | 77,40 m | — |
Uitstaande aandele | 192,32 m | — |
Prys om te bespreek | 11,98 | — |
Opbrengs op bates | -20,63% | — |
Opbrengs op kapitaal | -24,39% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -7,74 m | 60,73% |
Kontant van bedrywe | -5,82 m | 71,95% |
Kontant van beleggings | -10,02 m | 16,41% |
Kontant van finansiering | 844,00 k | -52,45% |
Netto kontantverandering | -15,00 m | 51,51% |
Beskikbare kontantvloei | -2,55 m | 76,57% |
Meer oor
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Gestig
2007
Webwerf
Werknemers
44
